Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.
Phase III long-term safety study of Effexor XR in patients with major depression...
Brief Summary
Official Title: “Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression”
Phase III long-term safety study of Effexor XR in patients with major depression.
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Effexor XR
Outcome Measures for this Clinical Trial
Primary Measures
- Incidence of adverse events
Secondary Measures
- Quantitative data for laboratory data
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)
Exclusion Criteria:
- Patients with schizophrenia or any other psychotic disorder
- Patients with history or presence of bipolar disorder
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Wyeth is now a wholly owned subsidiary of Pfizer Industry
Overall Clinical Trial Officials and Contacts
Medical Monitor Study Director Wyeth is now a wholly owned subsidiary of Pfizer
Additional Information
Information obtained from ClinicalTrials.gov on February 08, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00225524
Study ID Number: 0600B1-818
ClinicalTrials.gov Identifier: NCT00225524
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00225524
